Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

倍力腾 - NMPA Drug Approval Details

Approvals/NMPA/Belimumab powder for concentrate for solution for infusion

Approved

生物制品

Belimumab powder for concentrate for solution for infusion

GLAXOSMITHKLINE (IRELAND) LIMITED🇨🇳 National Medical Products Administration

Approval Date: Aug 23, 2024
Approval ID: 8beaJKrdei5
Company: GLAXOSMITHKLINE (IRELAND) LIMITED
Type: 生物制品

Approval Details

Approval Id: 8beaJKrdei5
Approval Number: 国药准字SJ20190032
Generic Name: 注射用贝利尤单抗
Generic Name En: Belimumab powder for concentrate for solution for infusion
Trade Name: 倍力腾
Drug Type: 生物制品
Dosage Form: 注射剂
Strength: 120mg/瓶
Reg Date: 2024-08-23
Expired Date: 2029-05-23
Company Name: GLAXOSMITHKLINE (IRELAND) LIMITED
Company Detail Path: /organization/glaxosmithkline-ireland-limited

Approved

Quick Info

Agency

NMPA

Country

🇨🇳

Approval Date

Aug 23, 2024

Approval ID

8beaJKrdei5

Type

生物制品

Back to NMPA Approvals